Recommendations and guidelines for the treatment of Clostridioides difficile infection in Taiwan.
J Microbiol Immunol Infect
; 53(2): 191-208, 2020 Apr.
Article
in En
| MEDLINE
| ID: mdl-32169531
ABSTRACT
Clostridioides difficile infection (CDI) is a major enteric disease associated with antibiotic use and a leading cause of hospital-acquired infections worldwide. This is the first guideline for treatment of CDI in Taiwan, aiming to optimize medical care for patients with CDI. The target audience of this document includes all healthcare personnel who are involved in the medical care of patients with CDI. The 2018 Guidelines Recommendations for Evidence-based Antimicrobial agents use in Taiwan (GREAT) working group was formed, comprising of infectious disease specialists from 13 medical centers in Taiwan, to review the evidence and draft recommendations using the grading of recommendations assessment, development, and evaluation (GRADE) methodology. A nationwide expert panel reviewed the recommendations during a consensus meeting in March 2019. The recommendation is endorsed by the Infectious Diseases Society of Taiwan (IDST). This guideline describes the epidemiology and risk factors of CDI, and provides recommendations for treatment of CDI in both adults and children. Recommendations for treatment of the first episode of CDI, first recurrence, second and subsequent recurrences of CDI, severe CDI, fulminant CDI, and pediatric CDI are provided.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Clostridium Infections
/
Guidelines as Topic
/
Anti-Bacterial Agents
Type of study:
Etiology_studies
/
Guideline
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Child
/
Humans
Country/Region as subject:
Asia
Language:
En
Journal:
J Microbiol Immunol Infect
Journal subject:
ALERGIA E IMUNOLOGIA
/
MICROBIOLOGIA
Year:
2020
Document type:
Article
Affiliation country: